Clinical Trial Update: A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of a Phase I/II trial evaluating OPN-305 in second-line lower-risk myelodysplastic syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• OPN-305 (OPN-305)

Snippet

Sponsor: Opsona Therapeutics Ltd. | Conditions: Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: COMPLETED